FindTrial
Sign In

Citrate for blood anticoagulation in continuous dialysis circuit

Regional citrate anticoagulation during CRRT: an experience from a single center in India

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/08/045125
Enrollment
100
Registered
2022-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N179- Acute kidney failure, unspecified

Interventions

Intervention1: Nil: Nil Intervention2: Regional citrate anticoagulation: The study aims to evaluate the protocol for routine use of Regional citrate anticoagulation during Continuous Renal Replacement

Sponsors

Anant Vikram Pachisia
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinical diagnosis of AKI using RIFLE, AKIN classification requiring CRRT and anticoagulation

Exclusion criteria

Exclusion criteria: Hyperkalemia: Potassium � 5.5 meq/l. Pregnant females

Design outcomes

Primary

MeasureTime frame
Average filter life with Regional Citrate Anticoagulation during CRRTTimepoint: Till the time filter is functioning—

Secondary

MeasureTime frame
1.Systemic blood iCa concentrations 2.Incidence new onset bleeding and site of bleeding 3.Incidence of citrate toxicityTimepoint: 1.Systemic blood iCa concentrations (Time: Baseline and up to 24 hoursââ?¬â?¢ post CRRT treatment cessation) 2. Incidence new onset bleeding and site of bleeding (Time: Baseline and up to 24 hoursââ?¬â?¢ post CRRT treatment cessation) 3. Incidence of citrate toxicity (Time: During the therapy with Regional Citrate Anticoagulation)—

Countries

India

Contacts

Public ContactAnant Vikram Pachisia

Medanta-The Medicity

anantndin@gmail.com9810368132

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026